314 related articles for article (PubMed ID: 29327284)
21. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?
Barkhof F; Hulst HE; Drulovic J; Uitdehaag BM; Matsuda K; Landin R;
Neurology; 2010 Mar; 74(13):1033-40. PubMed ID: 20200338
[TBL] [Abstract][Full Text] [Related]
22. Randomized trial comparing two different high doses of methylprednisolone in MS: a clinical and MRI study.
Oliveri RL; Valentino P; Russo C; Sibilia G; Aguglia U; Bono F; Fera F; Gambardella A; Zappia M; Pardatscher K; Quattrone A
Neurology; 1998 Jun; 50(6):1833-6. PubMed ID: 9633736
[TBL] [Abstract][Full Text] [Related]
23. Short-term effects of methylprednisolone on cerebral volume in multiple sclerosis relapses.
Chapman C; Tubridy N; Cook MJ; Mitchell PJ; MacGregor LR; Lovelock C; Litewka L; Sedal L; Kilpatrick TJ; Butzkueven H
J Clin Neurosci; 2006 Jul; 13(6):636-8. PubMed ID: 16790352
[TBL] [Abstract][Full Text] [Related]
24. A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS.
Ramo-Tello C; Grau-López L; Tintoré M; Rovira A; Ramió i Torrenta L; Brieva L; Cano A; Carmona O; Saiz A; Torres F; Giner P; Nos C; Massuet A; Montalbán X; Martínez-Cáceres E; Costa J
Mult Scler; 2014 May; 20(6):717-25. PubMed ID: 24144876
[TBL] [Abstract][Full Text] [Related]
25. Ring and nodular multiple sclerosis lesions: a retrospective natural history study.
Davis M; Auh S; Riva M; Richert ND; Frank JA; McFarland HF; Bagnato F
Neurology; 2010 Mar; 74(10):851-6. PubMed ID: 20211910
[TBL] [Abstract][Full Text] [Related]
26. Characterizing contrast-enhancing and re-enhancing lesions in multiple sclerosis.
Campbell Z; Sahm D; Donohue K; Jamison J; Davis M; Pellicano C; Auh S; Ohayon J; Frank JA; Richert N; Bagnato F
Neurology; 2012 May; 78(19):1493-9. PubMed ID: 22539575
[TBL] [Abstract][Full Text] [Related]
27. The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis.
Zivadinov R; Dwyer MG; Ramasamy DP; Davis MD; Steinerman JR; Khan O
J Neuroimaging; 2015; 25(6):989-95. PubMed ID: 26394270
[TBL] [Abstract][Full Text] [Related]
28. Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone.
Hoogervorst EL; Polman CH; Barkhof F
Mult Scler; 2002 Oct; 8(5):415-9. PubMed ID: 12356209
[TBL] [Abstract][Full Text] [Related]
29. A transcranial magnetic stimulation study evaluating methylprednisolone treatment in multiple sclerosis.
Fierro B; Salemi G; Brighina F; Buffa D; Conte S; La Bua V; Piazza A; Savettieri G
Acta Neurol Scand; 2002 Mar; 105(3):152-7. PubMed ID: 11886356
[TBL] [Abstract][Full Text] [Related]
30. Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data.
Cohen JA; Calabresi PA; Chakraborty S; Edwards KR; Eickenhorst T; Felton WL; Fisher E; Fox RJ; Goodman AD; Hara-Cleaver C; Hutton GJ; Imrey PB; Ivancic DM; Mandell BF; Perryman JE; Scott TF; Skaramagas TT; Zhang H;
Mult Scler; 2008 Apr; 14(3):370-82. PubMed ID: 18208877
[TBL] [Abstract][Full Text] [Related]
31. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial.
Le Page E; Veillard D; Laplaud DA; Hamonic S; Wardi R; Lebrun C; Zagnoli F; Wiertlewski S; Deburghgraeve V; Coustans M; Edan G; ;
Lancet; 2015 Sep; 386(9997):974-81. PubMed ID: 26135706
[TBL] [Abstract][Full Text] [Related]
32. Baseline clinical status as a predictor of methylprednisolone response in multiple sclerosis relapses.
Ramo-Tello C; Tintoré M; Rovira A; Ramió-Torrenta L; Brieva L; Saiz A; Cano A; Carmona O; Hervás JV; Grau-López L
Mult Scler; 2016 Jan; 22(1):117-21. PubMed ID: 26540732
[TBL] [Abstract][Full Text] [Related]
33. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
[TBL] [Abstract][Full Text] [Related]
34. Re-examining the effects of high-dose intravenous methylprednisolone for secondary progressive multiple sclerosis.
Jalipa FGU; Espiritu AI; Pasco PMD
Neurodegener Dis Manag; 2021 Apr; 11(2):177-185. PubMed ID: 33703936
[TBL] [Abstract][Full Text] [Related]
35. Monthly methylprednisolone in combination with interferon beta or glatiramer acetate for relapsing-remitting multiple sclerosis: A multicentre, single-blind, prospective trial.
Ozakbas S; Cinar BP; Kosehasanoğullari G; Kahraman T; Oz D; Kursun BB
Clin Neurol Neurosurg; 2017 Sep; 160():69-72. PubMed ID: 28689102
[TBL] [Abstract][Full Text] [Related]
36. Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy.
Salzer J; Svenningsson R; Alping P; Novakova L; Björck A; Fink K; Islam-Jakobsson P; Malmeström C; Axelsson M; Vågberg M; Sundström P; Lycke J; Piehl F; Svenningsson A
Neurology; 2016 Nov; 87(20):2074-2081. PubMed ID: 27760868
[TBL] [Abstract][Full Text] [Related]
37. Impact of methylprednisolone treatment on the expression of macrophage inflammatory protein 3alpha and B lymphocyte chemoattractant in serum of multiple sclerosis patients.
Michałowska-Wender G; Losy J; Biernacka-Łukanty J; Wender M
Pharmacol Rep; 2008; 60(4):549-54. PubMed ID: 18799824
[TBL] [Abstract][Full Text] [Related]
38. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
Sorensen PS; Mellgren SI; Svenningsson A; Elovaara I; Frederiksen JL; Beiske AG; Myhr KM; Søgaard LV; Olsen IC; Sandberg-Wollheim M
Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854
[TBL] [Abstract][Full Text] [Related]
39. Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum.
Koch MW; Mostert J; Zhang Y; Wolinsky JS; Lublin FD; Strijbis E; Cutter G
Neurology; 2021 Sep; 97(13):e1334-e1342. PubMed ID: 34376508
[TBL] [Abstract][Full Text] [Related]
40. The Impact of Methylprednisolone Pulses during Relapses of Multiple Sclerosis on the Kinetics of Anti-Interferon-Beta Antibodies.
Giantzi V; Karapanayiotides T; Lagoudaki R; Poulatsidou KN; Lourbopoulos A; Daniilidis M; Taskos N; Milonas I; Grigoriadis N
Eur Neurol; 2016; 75(1-2):82-8. PubMed ID: 26867030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
